Acoramidis not checked
Eidos Therapeutics, a BridgeBio company · AG10 · ALXN 2060
FollowEvery change as it happens, and a Monday email
Trials
5 active
12 in total · 5 in the EU
What this is
- How it works
- Transthyretin Stabilizer FDA class
- How it’s given
- “Study drug is defined as acoramidis 712 mg (equivalent to 800 mg acoramidis hydrochloride) taken orally twice daily for 36 months of open label treatment.”In the company’s words, NCT07695701 on ClinicalTrials.gov
- Tested for
- Amyloidosis (3 trials), Amyloid Cardiomyopathy (3 trials), Transthyretin Amyloidosis (2 trials), Amyloid Cardiomyopathy, Transthyretin-Related (2 trials), Cardiomyopathies (2 trials), Polyneuropathies (2 trials), Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM), Heart Diseases and 5 more
- Main trialPhase 4
- “The study aims to evaluate the effect of acoramidis on cardiac functional and structural improvement in participants with ATTR-CM.”In the company’s words, NCT07695701 on ClinicalTrials.gov
- Other names
- AG10 · ALXN 2060 · Eidos Therapeutics AG10
Other drugs for Amyloidosis
- NXC-201Nexcella Inc. · Phase 3
- NTLA-2001Intellia Therapeutics · Phase 3
- ALXN2220Alexion Pharmaceuticals, Inc. · Phase 3
- NucresiranAlnylam · Phase 3
- VutrisiranAlnylam · Phase 3
- SCTC21CSinocelltech · Phase 3
Coming up4
- 15 Apr 2028Phase 3 trial completes · ClinicalTrials.gov
- Aug 2030Phase 4 trial completes · ClinicalTrials.gov
- Oct 2031Phase 3 trial completes · ClinicalTrials.gov
- Nov 2037Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials12
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 4Recruiting | Aug 2030 | Cardiac Magnetic Resonance and Echocardiography Study With Acoramidis | |
| Phase 3Active, not recruiting | 15 Apr 2028 | Open-Label Safety Study of Acoramidis (AG10) in Symptomatic ATTR Participants | |
| Phase 3Recruiting | Oct 2031 | Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant | |
| Phase 3Not yet recruiting | Nov 2037 | To Evaluate the Long-term Safety and Tolerability of Acoramidis in Participants With Newly Diagnosed ATTR-CM (ACT-EARLY OLE) | |
| Phase 3Completed | 11 May 2023 | Efficacy and Safety of AG10 in Subjects With Transthyretin Amyloid Cardiomyopathy | |
| Phase 3Withdrawn | 31 Mar 2024 | Efficacy and Safety of AG10 in Subjects with Transthyretin Amyloid Polyneurophathy | |
| Phase 3Withdrawn | Sep 2026 | Efficacy and Safety of Acoramidis (AG10) in Subjects with Transthyretin Amyloid Polyneurophathy (ATTRibute-PN) | |
| Phase 2Completed | 5 Oct 2018 | Study of AG10 in Amyloid Cardiomyopathy | |
| Phase 2Terminated | 15 Sep 2025 | Open-Label Study of AG10 in Patients With Cardiomyopathy | |
| Phase 1Completed | 5 Feb 2018 | Single and Multiple Ascending Dose Study Assessing the Safety, Tolerability, PK and PD of AG10 | |
| Phase 1Completed | 4 Aug 2021 | A Single Dose Study to Evaluate the Pharmacokinetics of Acoramidis Modified Release Formulations in Healthy Subjects | |
| Phase 4Authorised | not given | Within-Patient Comparison of Serum Transthyretin Response to Tafamidis Versus Acoramidis: A Pilot Crossover Study in Transthyretin Amyloid Cardiomyopathy (ATTR-CM) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026